NASDAQ
PASW
Last Price
US $0.15
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Ping An Biomedical Co., Ltd. cash flow to debt ratio of -61.41% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Ping An Biomedical Co., Ltd.'s free cash flow has decreased -143.93% from $14.63M last year to $-6.43M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Ping An Biomedical Co., Ltd.'s debt to equity ratio is 0.23, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Ping An Biomedical Co., Ltd.'s debt has increased relative to shareholder equity from -1.50 last year to 0.23 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Ping An Biomedical Co., Ltd. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Ping An Biomedical Co., Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Ping An Biomedical Co., Ltd.'s profit margin has decreased (2.46K%) in the last year from -1.47% to -37.57%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Ping An Biomedical Co., Ltd.'s short-term assets of $63.70M exceed its short-term liabilities of $23.08M
Decreasing performance - ROA.
Ping An Biomedical Co., Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Ping An Biomedical Co., Ltd.'s return on equity of -67.43%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Ping An Biomedical Co., Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Ping An Biomedical Co., Ltd. had positive net income in only 2.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Ping An Biomedical Co., Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Ping An Biomedical Co., Ltd. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Ping An Biomedical Co., Ltd.'s yearly earnings has decreased 899.03% since last year from $-1.28M to $-12.83M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
Ping An Biomedical Co., Ltd.'s yearly revenue has decreased -61.03% since last year from $87.62M to $34.15M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -23.05% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Ping An Biomedical Co., Ltd.'s 3-year revenue CAGR of -33.20% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
Ping An Biomedical Co., Ltd. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Ping An Biomedical Co., Ltd. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Ping An Biomedical Co., Ltd. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Ping An Biomedical Co., Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Ping An Biomedical Co., Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Ping An Biomedical Co., Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Ping An Biomedical Co., Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Ping An Biomedical Co., Ltd. has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Ping An Biomedical Co., Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-67.43%
Return on equity
ROIC: -23.05%
Valuation History
0.00X
Price to Earnings
EV/EBITDA: -2.0X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $0.15
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.